Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


GSK to invest in new factories and drug R&D in Africa

31 March 2014, 12:30

London - GlaxoSmithKline plans to make new investments in additional factories and drug research in Africa, its chief executive said on Sunday, as the pharmaceuticals group broadens its bet on promising emerging markets.

Andrew Witty said the continent was important for the British company's long-term growth, adding that the investment would create jobs and build up healthcare capacity in a key region.

"The transformation of Africa into a successful growth region is one area that we need to focus on," Witty wrote in the Sunday Telegraph newspaper.

GSK, which already makes drugs in Kenya, Nigeria and South Africa, is now looking at sites for additional facilities in countries including Ghana, Ethiopia and Rwanda, a company spokeswoman said.

Witty will set out details of GSK's multimillion-pound investment plans for Africa at a conference in Brussels on Monday.

Sub-Saharan Africa currently accounts for only around 500 million pounds ($830 million) of GSK's annual sales, which totalled 26.5 billion pounds in 2013, but the group sees potential for significantly greater sales in future as African economies grow.

In particular, new opportunities are opening up for treating chronic diseases afflicting the middle classes, rather than just fire-fighting infections.

Non-communicable diseases like heart disease, lung disorders, diabetes and cancer are expected to account for 46 percent of all deaths in sub-Saharan Africa by 2030, up from 28 percent in 2008, according to the World Bank.

GSK has been stepping up its exposure to many of the world's developing economies by increasing local sales forces, striking deals and buying out minority shareholders in certain subsidiary businesses.

Last week it took full control of its consumer healthcare unit in Indonesia, after recently increasing its stake in local units in India.

Witty has made emerging markets a key growth platform for GSK and has stuck with the strategy despite recent problems in China, where sales have been hit by bribery allegations.

- Reuters


Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Submitted by
Shakila Alivitsa
Types of men that are a waste of ...

Most women end up heartbroken because they were trying to convince the wrong man to be in a relationship/ marriage. Read more...

Submitted by
Shakila Alivitsa
Cheating is hardwork!

Cheating, although enjoyable by the person doing it initially, it gets to a point they start realizing that it was never even worth it. Read more...

Submitted by
Shakila Alivitsa
Dating that one person that socie...

Works at a massage parlour. Works at Millionaires Club (that one on Baricho road) - you know the ones I am talking about. Read more...

Submitted by
Shakila Alivitsa
Submitted by
Shakila Alivitsa
What do men mean when they say th...

As much as men think they are the ones confused by relationships, they have a better idea of it than most women actually do. Read more...

Submitted by
Wilson Ochieng
ODM rebels sweat in Kisii as Oran...

ODM rebels are sweating in Kisii after the Orange Party won by elections despite concerted efforts by the ruling Jubilee Party to win the elections. Read more...